Neoplasm, Residual: all 272 studies

Page 3 of 3. Open to participants first (124), then studies with results posted, then the rest; newest registration first within each.

• Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual DiseaseStatus unknownNCT04209712Early Phase 1
• Next Generation Sequencing（NGS）Monitors Minimal Residual Disease（MRD）in Allo-PBSCT PatientsStatus unknownNCT04126967Not applicable
• Evaluation of Ultrasensitive Chromosomal Aneuploidy Detection for Detecting Minimal Residual Disease in Multiple MyelomaStatus unknownNCT04122092
• Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell TransplantTerminatedNCT04044560Phase 2
• Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or LymphomaWithdrawnNCT04029038Phase 1/2
• Allogeneic Donor Lymphocyte Infusions Combined With BlinatumomabWithdrawnNCT03982992Phase 2
• Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell TransplantationTerminatedNCT03951961Phase 2
• A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer PatientsActive, not recruitingNCT03945721Phase 1
• Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALLCompletedNCT03919526Phase 1
• Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive PatientsActive, not recruitingNCT03876769Phase 2
• An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual DiseaseWithdrawnNCT03770299Phase 2
• Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)WithdrawnNCT03699384Phase 1/2
• Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple MyelomaStatus unknownNCT03697655Phase 2
• The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AMLStatus unknownNCT03665480Phase 2/3
• HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCTStatus unknownNCT03662087Phase 2/3
• Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplantsStatus unknownNCT03624530Phase 2/3
• Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune RepertoireActive, not recruitingNCT03614689
• CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell TransplantationStatus unknownNCT03564977Not applicable
• Evaluation of Measurable Residual Disease in Patients With Acute Myeloid Leukemia as Surrogate Endpoint for SurvivalTerminatedNCT03549351
• Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUSCompletedNCT03521596
• Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual DiseaseActive, not recruitingNCT03516279Phase 2
• Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid LeukemiaWithdrawnNCT03515707Phase 2
• Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic SyndromeSuspendedNCT03494569Phase 1
• Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML PatientsCompletedNCT03488862
• Feasibility of the LUM Imaging System for Detection of Prostate CancerTerminatedNCT03441464Phase 1/2
• Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)No longer availableNCT03409081
• Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast CancerActive, not recruitingNCT03384914Phase 2
• Ultrasound in Psoriatic Arthritis TreatmentStatus unknownNCT03330769
• Minimal Residual Disease in Peripheral T-cell LymphomaCompletedNCT03297697
• Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After AllotransplantStatus unknownNCT03297528Phase 2
• New Markers for Minimal Residual Disease in Acute Lymphoblastic LeukemiaStatus unknownNCT03249636
• Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell MalignanciesActive, not recruitingNCT03241940Phase 1
• CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell MalignanciesActive, not recruitingNCT03233854Phase 1
• Measuring Molecular Residual Disease in Colorectal Cancer After Primary Surgery and Resection of MetastasesActive, not recruitingNCT03189576Not applicable
• Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic LeukemiaCompletedNCT03109093Phase 2
• Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)Approved for marketingNCT03070093
• Early Stereotactic Gamma Knife Radiosurgery to Residual Tumor After Surgery of Newly Diagnosed GlioblastomaSuspendedNCT03055208Not applicable
• MCLA-117 in Acute Myelogenous LeukemiaTerminatedNCT03038230Phase 1
• HBV-host cfDNA as Minimal Residual Tumor Marker for HBV-related HCCStatus unknownNCT03020342
• Laparoscopy for Primary Cytoreductive Surgery in Advanced Ovarian CancerCompletedNCT02980185
• Multicolour Versus Monocolour Specimens Inking After Pancreaticoduodenectomy for Periampullary CancerCompletedNCT02900950Not applicable
• Validation of a Method to Search Residual Disease in Auto-cryopreserved Ovarian TissuesCompletedNCT02900625
• Investigating Minimal Residual Disease in Autopreserved Ovarian Tissue in Cases of Neoplastic PathologyCompletedNCT02888145
• MRD-directed Therapy for Low-risk and Intermediate-risk AML.CompletedNCT02870777Phase 2/3
• International Randomised Phase III Clinical Trial in Children With Acute Myeloid LeukaemiaActive, not recruitingNCT02724163Phase 3
• Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL AmyloidosisCompletedNCT02716103
• Prognostic Role of Minimal Residual Disease in Acute Myeloid LeukemiaCompletedNCT02714790
• MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCTCompletedNCT02673008Phase 2/3
• Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer PatientsStatus unknownNCT02670109Phase 2
• Phase II Trial GA101 Inbrutinib B CLLCompletedNCT02666898Phase 2
• Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian CancerCompletedNCT02567253Phase 2
• Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL AmyloidosisCompletedNCT02555969
• CD19-Specific T-cells in Treating Patients With Advanced Lymphoid MalignanciesCompletedNCT02529813Phase 1
• Contamination of Testicle Tissue by RT-PCR in Participants With Solid TumorsStatus unknownNCT02400970
• Contamination of Ovarian Tissue by RT-PCR in Participants With Solid TumorsStatus unknownNCT02400827
• Assessment of the Minimal Residual Disease in DLBCL From Cell-free Circulating DNA by NGSCompletedNCT02339805Not applicable
• Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell TransplantationTerminatedNCT02338050Phase 2
• Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Cancer SurgeryCompletedNCT02314871Phase 4
• Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL)CompletedNCT02185781Phase 1
• Interferon α for the Therapy of Minimal Residual DiseaseStatus unknownNCT02185261Not applicable
• Safety Study of Dinutuximab Combined With Immunotherapy to Treat NeuroblastomaCompletedNCT02169609Phase 2
• Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell NeoplasmActive, not recruitingNCT02159495Phase 1
• TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic LeukemiaStatus unknownNCT01883219Phase 2
• Maintenance Therapy With Histamine Dihydrochloride and Interleukin-2 in Adult Acute Myeloid Leukemia (AML) Patients With Measurable Minimal Residual Disease (MRD)- a Non-interventional Study (NIS)TerminatedNCT01770158
• Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase InhibitorsTerminatedNCT01751425Phase 1
• Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute LeukemiaWithdrawnNCT01677949Phase 2
• Genetic Test in Detecting Minimal Residual Disease in Samples From Younger Patients Registered on the COG-AALL08B1 TrialCompletedNCT01629745
• Fractionated Radiosurgery for Painful Spinal MetastasesCompletedNCT01594892Not applicable
• Genetic Test To Identify Previously Undetectable Minimal Residual Disease in Cell Samples From Younger Patients With Acute Lymphoblastic LeukemiaCompletedNCT01533168
• Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)CompletedNCT01460498Phase 1
• Collection of Blood and Bone Marrow Samples From Select Patients With CML to Measure Minimal Residual DiseaseCompletedNCT00819143
• WT1 for the Detection of Minimal Residual DiseaseCompletedNCT00179829Phase 2/3

← Neoplasm, Residual overview